<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-35903" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Anorexia and Cachexia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ohnuma</surname>
            <given-names>Takao</given-names>
          </name>
          <aff>Icahn School of Medicine at Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ali</surname>
            <given-names>Muhammad Ashar</given-names>
          </name>
          <aff>Saint Clare's Denville Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adigun</surname>
            <given-names>Rotimi</given-names>
          </name>
          <aff>Touro University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Takao Ohnuma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Ashar Ali declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rotimi Adigun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-35903.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cachexia is a severe condition characterized by the significant loss of muscle mass and adipose tissue, commonly seen in patients with advanced cancer, chronic infections, and other long-term illnesses like chronic obstructive pulmonary disease and heart failure. This condition results from increased pro-inflammatory factors and leads to diminished quality of life, reduced treatment tolerance, and decreased survival. Cachexia management is challenging, with no fully satisfactory treatment available. Despite this, clinicians need to recognize that total parenteral nutrition has not been proven to significantly improve outcomes for patients undergoing chemotherapy or radiation therapy.</p>
        <p>In this course, participants learn to manage cancer cachexia by assessing nutritional status, identifying the underlying causes, and implementing tailored interventions. The course emphasizes a multidisciplinary approach, where collaboration between oncologists, dietitians, palliative care teams, and other healthcare professionals enhances patient outcomes. This interprofessional teamwork improves symptom management, ensures comprehensive nutritional support, and helps mitigate the adverse effects of cachexia on treatment tolerance and quality of life.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Screen patients undergoing cancer treatment for nutritional deficiencies and cachexia-related complications.</p></list-item><list-item><p>Implement evidence-based interventions for managing cancer cachexia, including nutritional support.</p></list-item><list-item><p>Assess the impact of cachexia on the patient's quality of life and treatment tolerance.</p></list-item><list-item><p>Strategize with the interprofessional team strategies&#x000a0;to&#x000a0;improve care coordination and communication to advance the treatment of cancer cachexia and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35903&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35903">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-35903.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cachexia is a significant loss of muscle and adipose tissue occurring in patients with advanced cancer, chronic obstructive pulmonary disease, chronic infection including acquired immunodeficiency syndrome and tuberculosis,&#x000a0;chronic heart failure,&#x000a0;and rheumatoid arthritis. Increases in proinflammatory factors characterize cachexia. There is a&#x000a0;decreased quality of life, decreased tolerance to surgical or medical interventions, and shortened survival.<xref ref-type="bibr" rid="article-35903.r1">[1]</xref><xref ref-type="bibr" rid="article-35903.r2">[2]</xref><xref ref-type="bibr" rid="article-35903.r3">[3]</xref></p>
        <p>The frequency and intensity of cachexia differ among cancers; patients with gastrointestinal, pancreatic, and lung cancers are more likely affected by cachexia than other tumors. By contrast, cachexia is relatively uncommon in patients with breast, sarcomas, and hematological malignancies.<xref ref-type="bibr" rid="article-35903.r4">[4]</xref><xref ref-type="bibr" rid="article-35903.r5">[5]</xref><xref ref-type="bibr" rid="article-35903.r6">[6]</xref>&#x000a0;Cachexia is not simply starvation; fat stores replace&#x000a0;glucose as the primary fuel.&#x000a0;Cancer causes a change in metabolism instead of an energy deficit, so conventional nutritional support is insufficient.</p>
      </sec>
      <sec id="article-35903.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Cancer-related cachexia can&#x000a0;be broken down into 3 categories:</p>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic derangement</p>
          </list-item>
          <list-item>
            <p>Anorexia</p>
          </list-item>
          <list-item>
            <p>Alimentary&#x000a0;tract dysfunction</p>
          </list-item>
        </list>
        <p>The&#x000a0;causes of cachexia can be related to disease, treatment, or emotional distress. Nausea, early satiety, and dysgeusia are factors in anorexia.</p>
        <p>
<bold>Cytokines</bold>
</p>
        <p>Mediators of cachexia associated with cancer include&#x000a0;tumor necrosis factor (TNF)-alpha, interleukins (IL) 1 and 6, ciliary neurotrophic factor, leukemia inhibitory factor, and interferon-gamma (IFN). These are produced by tumor cells and host immune cells and are procachectic factors, as they lead to anorexia, weight loss, protein and fat breakdown, an acute-phase protein response,&#x000a0;falls in insulin levels, insulin resistance,&#x000a0;rise in levels of cortisol and glucagon, fever,&#x000a0;anemia,&#x000a0;and elevated energy expenditure.<xref ref-type="bibr" rid="article-35903.r7">[7]</xref><xref ref-type="bibr" rid="article-35903.r8">[8]</xref></p>
        <p>Host immune cells, including macrophages, helper&#x000a0;T-cells type 1,&#x000a0;and myeloid-derived suppressor cells,&#x000a0;produce procachectic cytokines. Many tumors cause an elevated adrenergic state that results in an increased rate of energy expenditure. Skeletal muscle is the primary site of lean body mass depletion&#x000a0;as part of a persistent inflammatory response. Tumors only produce proteolysis-inducing (PIF) factors. TNF-alpha and PIF induce cachexia by activating the nuclear factor kappa B, a muscle transcription factor. This is secondary to increased protein turnover without equivalent protein synthesis.</p>
        <p>The IL-6 family ligands strongly activate the Janus-associated kinase (JAK)/signal transducers and activators of transcription (STAT) pathway.&#x000a0;STAT3 activation by IL-6 is necessary for muscle wasting. Inhibition of STAT3 pharmacologically using STAT3 or&#x000a0;JAK inhibitors reduces muscle atrophy. This indicates that STAT3 is a primary mediator of muscle wasting when there is high IL-6 family signaling.</p>
        <p>Anorexia and weight loss in patients with cancer do not correlate with serum levels of circulating&#x000a0; IL-1, IL-6, IFN-gamma, and&#x000a0;TNF-alpha.&#x000a0;There may be a central mechanism of action producing cachexia. Cytokines postulated to be involved in cachexia include TNF-alpha, IFN-alpha,&#x000a0;IL-1, IL-6, IL-8,&#x000a0;and others. Serotonin and dysfunction of neuropeptidergic circuits may be involved. Elevated plasma-free tryptophan&#x000a0;was observed in patients with cancer&#x000a0;and anorexia. This elevates tryptophan levels in the cerebrospinal fluid, resulting in&#x000a0;increased serotonin synthesis. High levels of serotonin contribute to cancer anorexia.</p>
        <p>
<bold>Insulin and Ghrelin</bold>
</p>
        <p>Insulin and leptin levels are proportional to body fat content, and central nervous system (CNS) concentrations&#x000a0;are proportional to plasma levels. Insulin secretion increases as&#x000a0;weight increases, which occurs&#x000a0;at the basal state and in response to meals. Leptin is more involved in CNS control of energy homeostasis than insulin, and leptin deficiency causes obesity with hyperphagia; this persists despite high insulin levels.</p>
        <p>Ghrelin function is a peptide produced by ghrelin cells in the gastrointestinal tract, is secreted when the stomach is empty, and acts in the CNS. The secretion stops when the stomach&#x000a0;is stretched. Ghrelin increases hunger, gastric acid, secretion, and gastrointestinal motility centrally. The same brain cells have receptors for ghrelin and leptin, with opposing effects.<bold>&#x000a0;</bold></p>
        <p>
<bold>Alimentary Tract Dysfunction</bold>
</p>
        <p>Patients with cancer often have abnormalities in their taste and smell, and tumors of the mouth, neck, esophagus, and stomach may impair oral intake. Obstruction can occur in tumors of the pancreas, liver, and peritoneum; intestinal obstruction is common. Enzymatic insufficiency secondary to pancreatic insufficiency may contribute to malabsorption. Lymphoma of the intestine or mesentery can result in issues.</p>
        <p>Slowing of peristalsis and delayed gastric emptying&#x000a0;contribute to early satiety.&#x000a0;Chemotherapy commonly causes nausea, vomiting, mucositis, and abnormal perception of taste. Stomatitis, alterations in taste and smell, and&#x000a0;xerostomia&#x000a0;often occur secondary to radiotherapy to the head and neck. Abdominal radiation therapy can cause nausea, vomiting, anorexia, diarrhea, and malabsorption.<xref ref-type="bibr" rid="article-35903.r9">[9]</xref><xref ref-type="bibr" rid="article-35903.r10">[10]</xref><xref ref-type="bibr" rid="article-35903.r11">[11]</xref></p>
        <p>
<bold>Biochemical and Metabolic Derangement</bold>
</p>
        <p>Neoplastic cells have high levels of glucose utilization and production&#x000a0;of lactic acid, a condition known as the&#x000a0;Warburg effect. Hexokinase is the first step of the glycolytic pathway, and overexpression in tumor cells contributes to this process. Tumor glycolysis and host gluconeogenesis may be a significant cause of cancer cachexia. Recently, an extensive re-examination of the Warburg effect shows that, unlike most cells, numerous cancer cell lines obtain a significant portion of their energy from aerobic glycolysis.&#x000a0;Many malignant cells secrete hydrogen peroxide, and oxygen-free radicals drive mitophagy, aerobic glycolysis, and&#x000a0;autophagy.</p>
        <p>
<bold>Theorized Causes of Cancer Anorexia</bold>
</p>
        <p>Cancer anorexia may be caused by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cytokines, TNF-alpha, IL-1, IL-6</p>
          </list-item>
          <list-item>
            <p>Serum lactate</p>
          </list-item>
          <list-item>
            <p>Neuropeptides</p>
          </list-item>
          <list-item>
            <p>Glucagon and similar peptides</p>
          </list-item>
          <list-item>
            <p>Bombesin</p>
          </list-item>
          <list-item>
            <p>Serotonin</p>
          </list-item>
          <list-item>
            <p>Cisplatin, nitrogen mustard, doxorubicin, and other&#x000a0;chemotherapeutic agents</p>
          </list-item>
          <list-item>
            <p>Hypercalcemia</p>
          </list-item>
          <list-item>
            <p>Satietins</p>
          </list-item>
          <list-item>
            <p>Toxohormone-L</p>
          </list-item>
        </list>
        <p>
<bold>Orexigenic and Anorexigenic Neuropeptides</bold>
</p>
        <p>
<bold>Orexigenic molecules</bold>
</p>
        <p>Orexigenic&#x000a0;molecules that may play a role in cancer-related cachexia include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypocretin 1 and 2&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cocaine and amphetamine-regulated transcript&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Agouti-related protein&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Galanin</p>
          </list-item>
          <list-item>
            <p>Ghrelin</p>
          </list-item>
          <list-item>
            <p>Neuropeptide Y&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Melanin-concentrating hormone&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Anorexigenic molecules</bold>
</p>
        <p>Anorexigenic&#x000a0;molecules&#x000a0;that may play a role in cancer-related cachexia include:</p>
        <list list-type="bullet">
          <list-item>
            <p>a-melanocyte-stimulating hormone&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bombesin</p>
          </list-item>
          <list-item>
            <p>Calcium-gene related peptide</p>
          </list-item>
          <list-item>
            <p>Cholecystokinin</p>
          </list-item>
          <list-item>
            <p>Cocaine and amphetamine-regulated transcript&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Corticotropin-releasing hormone&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Urocortin&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dopamine</p>
          </list-item>
          <list-item>
            <p>Glucagon-like peptide 1&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Histamine</p>
          </list-item>
          <list-item>
            <p>Insulin</p>
          </list-item>
          <list-item>
            <p>Neurotensin</p>
          </list-item>
          <list-item>
            <p>Leptin</p>
          </list-item>
          <list-item>
            <p>IL-1b</p>
          </list-item>
          <list-item>
            <p>Oxytocin</p>
          </list-item>
          <list-item>
            <p>Pro-opiomelanocortin&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Serotonin</p>
          </list-item>
          <list-item>
            <p>Thyrotropin-releasing hormone&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-35903.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The cachexia&#x000a0;prevalence ranges from 5% to 15% in congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) to 60% to 80% in advanced cancer. Mortality rates of patients with COPD and cachexia are 10% to 15% per year. In patients with cachexia and CHF or chronic kidney disease, mortality is 20% to 30% per year, and it is 80% in patients with cachectic cancer.<xref ref-type="bibr" rid="article-35903.r12">[12]</xref></p>
      </sec>
      <sec id="article-35903.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Signaling Pathways</bold>
</p>
        <p>The multiple signaling pathways that cause muscle atrophy are interdependent; these include:&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Autophagic-lysosomal pathway</p>
          </list-item>
          <list-item>
            <p>Insulin-like growth factor-1 pathway</p>
          </list-item>
          <list-item>
            <p>Dystrophin-glycoprotein complex&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Calcium-dependent proteolysis system</p>
          </list-item>
          <list-item>
            <p>Mitogen-activated protein kinases</p>
          </list-item>
          <list-item>
            <p>IL-6, JAK/STAT pathway</p>
          </list-item>
          <list-item>
            <p>Myostatin/activin pathway</p>
          </list-item>
          <list-item>
            <p>Poly(adenosine diphosphate-ribose) polymerase</p>
          </list-item>
          <list-item>
            <p>Nuclear factor kappa-light-chain-enhancer of activated&#x000a0;B&#x000a0;cell-dependent pathway (including&#x000a0;tumor necrosis factor-like weak inducer of apoptosis)</p>
          </list-item>
          <list-item>
            <p>Ubiquitin-proteasome pathway&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>Inhibition or activation of a single path&#x000a0;often causes a&#x000a0;cascade affecting muscle protein balance, and cancer-related cachexia results in the metabolic reprogramming of muscle and&#x000a0;fatty tissues. Fatty acids are catabolized by cancer cells to provide energy for&#x000a0;tumor growth. Invasion of adipose tissue by cancer cells induces the release of free fatty acids from adjacent adipocytes. Autophagy and lysosomal degradation result in muscle wasting. Hormone-sensitive lipase and adipose triglyceride lipase knockdown studies reveal that they mediate muscle degradation.</p>
        <p>
<bold>Selective Parasitism</bold>
</p>
        <p>There is selective parasitism by the tumor of the host. There is competition for substrates, with tumors acting as&#x000a0;nitrogen traps independent of protein intake. Given that the total tumor mass in most patients is usually less than 550 g and that patients with tiny tumors can have cachexia, it is doubtful that simple competition for nitrogen is responsible for cachexia.</p>
      </sec>
      <sec id="article-35903.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The definition of cancer cachexia includes weight loss of more than 5% over 12 months, body mass index of less than 20, or sarcopenia, as evidenced by dual-energy x-ray absorptiometry.</p>
      </sec>
      <sec id="article-35903.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluating a patient with cachexia includes monitoring blood chemistry and body weight. Bioelectrical impedance has also&#x000a0;been used.<xref ref-type="bibr" rid="article-35903.r13">[13]</xref><xref ref-type="bibr" rid="article-35903.r14">[14]</xref></p>
        <p>
<bold>Stages of Cancer Cachexia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pre-cachexia:</bold> There is anorexia and metabolic change with a weight loss of 5% or less.</p>
          </list-item>
          <list-item>
            <p><bold>Cachexia:</bold>&#x000a0;The body mass index is less than 20, and weight loss is more than 2%, or systemic sarcopenia and weight loss is more than 2%.</p>
          </list-item>
          <list-item>
            <p><bold>Refractory cachexia:</bold>&#x000a0;The cancer&#x000a0;is usually unresponsive, the performance score is low, and the predicted survival is less than 3 months.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-35903.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Removal of the tumor is the best treatment for cancer cachexia. When definitive treatment is not possible, there has been some&#x000a0;success with multiple treatment modalities.<xref ref-type="bibr" rid="article-35903.r15">[15]</xref><xref ref-type="bibr" rid="article-35903.r16">[16]</xref><xref ref-type="bibr" rid="article-35903.r17">[17]</xref></p>
        <p>
<bold>Supportive Care</bold>
</p>
        <p>Intervention from the stage of precachexia is best. Early nutritional intervention can improve nutritional status. This may reduce the inflammatory response. Body weight stabilization during chemotherapy often reduces toxicity and improves overall survival. The following have all shown limited success:</p>
        <list list-type="bullet">
          <list-item>
            <p>Antiemetics</p>
          </list-item>
          <list-item>
            <p>Exogenous pancreas extract&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Frequent small feedings</p>
          </list-item>
          <list-item>
            <p>Homemade food supplements may be better tolerated</p>
          </list-item>
          <list-item>
            <p>Oral and&#x000a0;parenteral nutritional supplements</p>
          </list-item>
          <list-item>
            <p>Treatment of stomatitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Transfusions of blood components</p>
          </list-item>
        </list>
        <p>
<bold>Exercise</bold>
</p>
        <p>Exercise is safe during active cancer treatments as it improves muscle strength, bone health, and quality of life while decreasing depression,&#x000a0;fatigue,&#x000a0;and psychosocial distress. Physical activity can reduce the risk of comorbidities negatively affecting cancer survivors. Evidence indicates that exercise is associated with a reduction in overall mortality. Physical exercise can improve insulin sensitivity, modulate muscle metabolism, and reduce inflammation. Exercise has anti-inflammatory benefits; it up-regulates anti-inflammatory cytokines in skeletal muscle and adipose tissue. Recommendations should be made to exercise early in cancer treatment, and physical therapy evaluation can be helpful. Caregiver participation improves compliance.</p>
        <p>
<bold>Pharmacologic Management</bold>
</p>
        <p>Multiple agents with different mechanisms of action can be used alone or in combination, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Olanzapine</bold>, a&#x000a0;selective monoaminergic antagonist, has a strong affinity for dopamine and serotonin receptors. This drug has been used at low doses, showing improved weight and nutritional status and low incidence of side effects.</p>
          </list-item>
          <list-item>
            <p><bold>Ghrelin and its analogs</bold>, including anamorelin, are helpful in some patients with cachexia. Adverse events included nausea and hyperglycemia.</p>
          </list-item>
          <list-item>
            <p><bold>Recombinant-human GH with insulin</bold> has been evaluated, and the whole-body protein net balance has improved.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Anabolic-androgenic steroids</bold> have been used to promote muscle growth and strength. Nandrolone decanoate was studied in patients with non-small cell lung cancer. The treated group had less weight loss, but survival was comparable. Fluoxymesterone, an anabolic steroid, was found to be&#x000a0;inferior to megestrol acetate or dexamethasone.</p>
          </list-item>
          <list-item>
            <p><bold>Enobosarm (GTx-024)</bold> is an androgen receptor modulator. This drug has tissue-selective anabolic effects in muscle and bone. Results from one study showed an increase in lean body mass.</p>
          </list-item>
          <list-item>
            <p><bold>Thalidomide</bold> suppresses TNF production in patients with&#x000a0;cancer and has been combined with medroxyprogesterone or megestrol acetate, oral eicosapentaenoic acid, and L-carnitine, resulting in a significant increase in lean body mass, decreased fatigue, and improved appetite.</p>
          </list-item>
          <list-item>
            <p><bold>MABp1 (Xilonix; Xbiotech, Inc, Austin, TX)</bold> is&#x000a0;a fully humanized, monoclonal anti-IL-1a antibody. This drug is a receptor antagonist that results in partial remission or stabilization of cachexia.</p>
          </list-item>
          <list-item>
            <p><bold>Corticosteroids</bold> have been found in results from uncontrolled studies to diminish anorexia, asthenia, and pain in patients with cancer. The improvements did not persist, and all nutritional status returned to baseline with no differences in the mortality rate.</p>
          </list-item>
          <list-item>
            <p><bold>Megestrol acetate</bold> has been used historically to improve appetite and increase body fat more than lean body mass. There is a reduction of serum levels of IL-1a and b, IL-2, IL-6, and TNF-a.</p>
          </list-item>
          <list-item>
            <p><bold>Medroxyprogesterone acetate</bold> is also a synthetic progestagen that has been used to reduce the production of cytokines and serotonin. This drug increases appetite in patients with cancer but does not cause weight gain.</p>
          </list-item>
          <list-item>
            <p><bold>Metoclopramide</bold> can be used for patients with delayed gastric emptying or gastroparesis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Dronabinol and marijuana dronabinol (delta 9-tetrahydrocannabinol, THC)</bold> have been studied. Cannabinoids&#x000a0;have not shown to be&#x000a0;more effective than megestrol despite improved appetite.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>The anti-TNF antibody</bold> has been studied&#x000a0;with conflicting results.</p>
          </list-item>
          <list-item>
            <p><bold>Eicosapentaenoic acid</bold> was found to have antitumor and anti-cachexia activities in animal cachexia models, but randomized clinical studies show no unique benefits.</p>
          </list-item>
          <list-item>
            <p><bold>Myostatin inhibitors</bold> may be a new potential therapeutic target. Activin type-2 receptor (ActRIIB) has been&#x000a0;used to treat muscle wasting. ActRIIB is a high-affinity activin type 2 receptor known to mediate the signaling via a subset of transforming growth factor-b family ligands, including myostatin,&#x000a0;activin, growth differentiation factor 11, and others.</p>
          </list-item>
          <list-item>
            <p><bold>Bimagrumab</bold> is a fully humanized anti-ActRII monoclonal antibody that&#x000a0;is to be studied for non-small cell lung cancer-associated cachexia.</p>
          </list-item>
          <list-item>
            <p><bold>NSAIDs, including indomethacin and celecoxib</bold>, have not been shown to improve nutritional status.</p>
          </list-item>
          <list-item>
            <p><bold>Hydrazine sulfate</bold> is an inhibitor of the enzyme phosphoenolpyruvate carboxykinase that interrupts gluconeogenesis in animals. Results from studies have shown no benefit.</p>
          </list-item>
          <list-item>
            <p><bold>Beta-hydroxy-beta-methyl butyrate with L-arginine and L-glutamine</bold> has been used for cachexia. This is a metabolite of leucine and interferes with the activation of nuclear factor kappa-light-chain-enhancer of activated&#x000a0;B&#x000a0;cells. In tumor-bearing mice, it inhibited proteolysis-inducing factor-induced protein degradation and&#x000a0;attenuated the increased protein degradation.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>OHR/AVR118 (OHR Pharmaceuticals, Inc, New York, NY)</bold> is a broad-spectrum peptide-nucleic acid immunomodulator theorized to have cytoprotective properties. Results from a study in patients with cancer showed stabilization of body and muscle mass, increased appetite, and enhanced quality of life.</p>
          </list-item>
          <list-item>
            <p><bold>Total parenteral nutrition</bold>&#x000a0;has not been shown to significantly benefit patients undergoing chemotherapy or radiation therapy regarding tolerance, response, or survival.</p>
          </list-item>
          <list-item>
            <p><bold>Cyproheptadine</bold> is a serotonin and histamine receptor antagonist that can help with weight gain in patients with carcinoid tumors.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-35903.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for anorexia and cachexia include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Achalasia</p>
          </list-item>
          <list-item>
            <p>Avoidant restrictive food intake disorder</p>
          </list-item>
          <list-item>
            <p>Binge eating disorder&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cancer</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Crohn disease</p>
          </list-item>
          <list-item>
            <p>Cystic fibrosis</p>
          </list-item>
          <list-item>
            <p>Dementia, tuberculosis</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Irritable bowel syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Panhypopituitarism</p>
          </list-item>
          <list-item>
            <p>Protein-losing enteropathy</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-35903.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about anorexia and cachexia are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Early recognition and intervention of cachexia improve&#x000a0;the quality of&#x000a0;life and survival.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Physical exercise should be a component of anticachexia protocols.</p>
          </list-item>
          <list-item>
            <p>Drugs needing more study include growth hormone-releasing peptide&#x000a0;2 and growth hormone-releasing hormone expression plasmids.</p>
          </list-item>
          <list-item>
            <p>A combination of anticachexia agents can be beneficial.</p>
          </list-item>
          <list-item>
            <p>Ghrelin analogs, including anamorelin, show the most promise.</p>
          </list-item>
          <list-item>
            <p>Medroxyprogesterone acetate, celecoxib, cannabinoids, and antioxidants are used.</p>
          </list-item>
          <list-item>
            <p>Drugs being studied include ghrelin mimetics such as BIM-28131, BIM-28125, L163 255, and RC-1291.
<list list-type="bullet"><list-item><p>Enobosarm is an&#x000a0;androgen receptor modulator.</p></list-item><list-item><p>MT-102 is an&#x000a0;anabolic-catabolic transforming agent.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>New drug targets include&#x000a0;proinflammatory cytokine inhibitors&#x000a0;and myostatin inhibitors.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-35903.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cancer cachexia is a well-known problem for many patients with advanced malignancy. The cause of cachexia is multifactorial and is best managed by an interprofessional team that consists of an oncologist, oncology nurse, dietitian, social worker, pharmacist, physical therapist, and a mental health counselor. The key is to recognize the problem early when treatment is most successful. Even though many pharmacological agents may help boost appetite, long-term&#x000a0;studies on the effectiveness of these agents are lacking. At a minimum, the patient should be seen by a dietitian&#x000a0;and a therapist. Improving the mood and offering supportive services may also help. Sadly, when cancer cachexia is advanced, the outlook for most patients is poor, and thus, one should always try to ensure that the quality of life does not deteriorate.<xref ref-type="bibr" rid="article-35903.r18">[18]</xref><xref ref-type="bibr" rid="article-35903.r19">[19]</xref></p>
        <p>The oncology nurse should focus on monitoring the patient and ensuring regular follow-up appointments are maintained. Family education by the nurse is essential. If the patient has signs of cachexia, the nurse should report their concerns to the clinician managing the case. The pharmacist also plays a role, and often, the pharmacist can provide additional pharmaceutical solutions that may help control the patient. Further, with the complexity of the combination of medical therapy, reconciliation of the medications and reporting to the clinician if there is a concern of medication combinations that may worsen the condition is essential. While extremely challenging, an interprofessional team providing care can achieve the best outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-35903.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35903&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35903">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/nutrition/anorexia-and-cachexia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=35903">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/35903/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=35903">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-35903.s13">
        <title>References</title>
        <ref id="article-35903.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Fabbro</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy in cachexia.</article-title>
            <source>Ann Palliat Med</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-66</page-range>
            <pub-id pub-id-type="pmid">30180745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turcott</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>O&#x000f1;ate-Oca&#x000f1;a</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Soca-Chafre</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ram&#x000ed;rez-Tirado</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Flores-Estrada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zatarain-Barr&#x000f3;n</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>Arrieta</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>FAACT-Anorexia Cachexia Scale: Cutoff Value for Anorexia Diagnosis in Advanced Non-Small Cell Lung Cancer Patients.</article-title>
            <source>Nutr Cancer</source>
            <year>2019</year>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>409</fpage>
            <page-range>409-417</page-range>
            <pub-id pub-id-type="pmid">30273069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hopkinson</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Psychosocial Support in Cancer Cachexia Syndrome: The Evidence for Supported Self-Management of Eating Problems during Radiotherapy or Chemotherapy Treatment.</article-title>
            <source>Asia Pac J Oncol Nurs</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>358</fpage>
            <page-range>358-368</page-range>
            <pub-id pub-id-type="pmid">30271817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peixoto da Silva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>JMO</given-names>
              </name>
              <name>
                <surname>Costa E Silva</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Gil da Costa</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia.</article-title>
            <source>J Cachexia Sarcopenia Muscle</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>619</fpage>
            <page-range>619-635</page-range>
            <pub-id pub-id-type="pmid">32142217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takayama</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>[Overview of Cancer-Associated Cachexia].</article-title>
            <source>Gan To Kagaku Ryoho</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>1814</fpage>
            <page-range>1814-1817</page-range>
            <pub-id pub-id-type="pmid">31879394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhanapal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saraswathi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Govind</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Cancer cachexia.</article-title>
            <source>J Oral Maxillofac Pathol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>257</fpage>
            <page-range>257-60</page-range>
            <pub-id pub-id-type="pmid">22144825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ruan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Targeting both sides of the GDF15-GFRAL-RET receptor complex: A new approach to achieve body weight homeostasis.</article-title>
            <source>Genes Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>183</fpage>
            <page-range>183-184</page-range>
            <pub-id pub-id-type="pmid">30258922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>VWW</given-names>
              </name>
              <name>
                <surname>Husaini</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sainsbury</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Breit</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.</article-title>
            <source>Cell Metab</source>
            <year>2018</year>
            <month>Sep</month>
            <day>04</day>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>353</fpage>
            <page-range>353-368</page-range>
            <pub-id pub-id-type="pmid">30184485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qiang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews.</article-title>
            <source>BMC Complement Altern Med</source>
            <year>2018</year>
            <month>Aug</month>
            <day>09</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>236</fpage>
            <pub-id pub-id-type="pmid">30092794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rassy</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Ghosn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rassy</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Assi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Do immune checkpoint inhibitors perform identically in patients with weight extremes?</article-title>
            <source>Immunotherapy</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>733</fpage>
            <page-range>733-736</page-range>
            <pub-id pub-id-type="pmid">30008261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arrieta</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Luvi&#x000e1;n-Morales</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turcott</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>O&#x000f1;ate-Oca&#x000f1;a</surname>
                <given-names>LF</given-names>
              </name>
            </person-group>
            <article-title>Quality of life and anorexia/cachexia in lung cancer: validation of the Spanish version of the FAACT instrument.</article-title>
            <source>Qual Life Res</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>2709</fpage>
            <page-range>2709-2718</page-range>
            <pub-id pub-id-type="pmid">29987501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barajas Galindo</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Vidal-Casariego</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calleja-Fern&#x000e1;ndez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Moreno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pintor de la Maza</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pedraza-Lorenzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>&#x000c1;vila-Turcios</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Alejo-Ramos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villar-Taibo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Urioste-Fondo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cano-Rodr&#x000ed;guez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ballesteros-Pomar</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Appetite disorders in cancer patients: Impact on nutritional status and quality of life.</article-title>
            <source>Appetite</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>114</volume>
            <fpage>23</fpage>
            <page-range>23-27</page-range>
            <pub-id pub-id-type="pmid">28315777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo-Mart&#x000ed;nez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Castro-Eguiluz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Copca-Mendoza</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Camargo</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Reyes-Torres</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>&#x000c1;vila</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-C&#x000f3;rdova</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fuentes-Hern&#x000e1;ndez</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Cetina-P&#x000e9;rez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Milke-Garc&#x000ed;a</surname>
                <given-names>MDP</given-names>
              </name>
            </person-group>
            <article-title>Nutritional Assessment Tools for the Identification of Malnutrition and Nutritional Risk Associated with Cancer Treatment.</article-title>
            <source>Rev Invest Clin</source>
            <year>2018</year>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>121</fpage>
            <page-range>121-125</page-range>
            <pub-id pub-id-type="pmid">29943772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serpe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Demurtas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Puzzoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Madeddu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scartozzi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Cancer cachexia assessment: new tools for oncologists.].</article-title>
            <source>Recenti Prog Med</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>107</volume>
            <issue>10</issue>
            <fpage>515</fpage>
            <page-range>515-524</page-range>
            <pub-id pub-id-type="pmid">27782227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cramer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kestenbaum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Durazo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Downey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Geluz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Roeland</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based Palliative Care Approaches to Non-pain Physical Symptom Management in Cancer Patients.</article-title>
            <source>Semin Oncol Nurs</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-240</page-range>
            <pub-id pub-id-type="pmid">30120000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mattox</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Cancer Cachexia: Cause, Diagnosis, and Treatment.</article-title>
            <source>Nutr Clin Pract</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>599</fpage>
            <page-range>599-606</page-range>
            <pub-id pub-id-type="pmid">28825869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arends</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baracos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bertz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bozzetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Calder</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Deutz</surname>
                <given-names>NEP</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laviano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lisanti</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lobo</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Muscaritoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ockenga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pirlich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Strasser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de van der Schueren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Gossum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vaupel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Weimann</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>ESPEN expert group recommendations for action against cancer-related malnutrition.</article-title>
            <source>Clin Nutr</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>1187</fpage>
            <page-range>1187-1196</page-range>
            <pub-id pub-id-type="pmid">28689670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Horiguchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tasaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asakuma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asano</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Impact of body mass index on clinicopathological outcomes in patients with renal cell carcinoma without anorexia-cachexia syndrome.</article-title>
            <source>Mol Clin Oncol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-53</page-range>
            <pub-id pub-id-type="pmid">29387396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35903.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>What is next after anamorelin?</article-title>
            <source>Curr Opin Support Palliat Care</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>266</fpage>
            <page-range>266-271</page-range>
            <pub-id pub-id-type="pmid">28957883</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
